Tag: LRRK2

Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential

Weisman, D. & McKeith, I. Dementia with Lewy Bodies. Semin. Neurol. 27, 042–047 (2007). Article  Google Scholar  Foguem, C. & Manckoundia, P. Lewy Body Disease: Clinical and Pathological “Overlap Syndrome” Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease). Curr. Neurol. Neurosci. Rep. 2018 18:5 18, 1–9 (2018). CAS  Google Scholar …

Continue Reading Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential

Dosing Begins for LIGHTHOUSE, Parkinson’s Clinical Trial of BIIB122

Dosing has begun in LIGHTHOUSE, a Phase 3 clinical trial testing BIIB122 — an experimental inhibitor of LRRK2 being developed by Biogen and Denali Therapeutics — in patients with early-stage Parkinson’s disease. The study (NCT05418673), underway at two clinical sites in Colorado and Florida, is recruiting up to 400 patients…

Continue Reading Dosing Begins for LIGHTHOUSE, Parkinson’s Clinical Trial of BIIB122